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Background: Male breast cancer (MBC) is an uncommon disease that has been the focus of limited research. It is
estimated that approximately 10% of men with breast cancer have a genetic predisposition, with BRCA2 being the
most prevalent genetic mutation. Here we describe the case of MBC in a 64-year-old man who presented on physical
examination a nodule in his left breast and declared to have an extensive family history of cancer.
Methods and results: The patient was firstly diagnosed with an invasive ductal carcinoma (IDC) with histological
grade III, nuclear grade 3, pT4N2Mx and positive for hormonal receptors and HER2. Exome sequencing was performed
by massive parallel sequencing which had detected a novel BRCA2 germline mutation that is a large genomic deletion
of 3,492 nucleotides including BRCA2 exon 14, and this deletion is out of frame and is predicted to lead to a stop
codon in exon 15 at codon 2,496.
Conclusion: Large rearrangements in BRCA1 and BRCA2 occur in a small percentage (<1%) of patients tested for
hereditary breast and ovarian cancer. This is the first report of the mutation del3492 in BRCA2 exon 14, which
leads to a truncated protein and therefore is clinically relevant. Mutation segregation analysis should be
further done in the Brazilian population. Herein we highlight the importance of next-generation sequencing
in the detection of large genomic deletions.
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identify a small subset of individual patients and families
who have increased cancer risk because of the presence
of mutations in cancer susceptibility genes. In the major-
ity of cases however, specific mutations have not yet
been identified or cancers have arisen sporadically in the
context of various risk factors, including a positive fam-
ily history [1]. BRCA1 and BRCA2 are genes with large
coding sequences, consisting of 51 exons in total and a
large number of mutations have been characterized world-
wide. Together, germline mutations in these two genes are
considered to constitute approximately 6–7% of breast* Correspondence: pesquisaclinica.tirzah@yahoo.com
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unless otherwise stated.cancers and 10% of ovarian cancers, but these numbers
vary between populations. More than 2000 different muta-
tions are reported in the Breast Cancer Information Core
(BIC) database [2] and the majority of mutations de-
scribed are frameshift mutations which result in a trun-
cated protein. Male breast cancer (MBC) accounts for less
than 1% of all male cancers and 0.65% of all breast tumors
[3-5], and men tend to be diagnosed at an older age than
women (mean age is about 67 years). It is an infrequent,
poorly characterized disease which is epidemiologically
and biologically different from female breast cancer
(FBC), and it is still unknown whether current paradigms
and treatment of female disease can be extrapolated to
MBC [6]. Decreased awareness of the existence of such a
disease among male patients and physicians leads to its
late presentation, where the majority of cases are invasivel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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noses. The incidence of MBC has increased about 26% over
the past 25 years, similarly to FBC [7,8]. Extensive know-
ledge about female BRCA1/2 and other inherited germline
mutations are available, whereas little is known of male tu-
mors from high-risk families. Besides this, mutation detec-
tion and estimation of prevalence of MBC are restricted
to North America and Europe, while data from other pop-
ulations, such as Brazil, are scarce [9]. In a recent article,
Thuler and Bergmann have published a retrospective co-
hort study with clinical-epidemiological characteristics of
1189 Brazilian male breast cancer patients and the results
have showed an increase in the incidence and mortality in
MBC in Brazil [10] but there is no data concerning mo-
lecular aspects. Moreover, the majority of known BRCA2
mutations are point mutations detected by Sanger sequen-
cing which is unable to detect large deletions and amplifi-
cations of complete exons. The present study reports a
man harboring a deletion of 3,492 nucleotides in exon 14
of BRCA2 gene. To our knowledge, this is the first MBC
reporting a BRCA2 mutation in Brazil, showing the ab-
sence of this kind of study in this population. This study
brings a new insight about methodology used to screen
for germline BRCA2 mutation.
A 64 year-old man reported a painful node in the left
breast since 2 years (2008). He related a strong familial
breast cancer history (father dead - prostate cancer, mother
and six sisters dead - breast cancer, four out of five broth-
ers dead – cancer not identified) (Figure 1). He denied
using drugs or anabolic steroids and did not drink large
amounts of alcohol. On physical examination, an irregular
sub areolar node was detected. Although gynecomastia
has been suggested to be present in 6-38% of breastFigure 1 Patient pedigree. II.3 is the proband (indicated by an arrow). Th
of prostate cancer (I.1). Mother and sisters dead of breast cancer (I.2, II.6, II.7
cancer (II.1, 2, 4, 5). Two daughters from first marriage also have been diag
indicated (Dx).cancer cases in men, it was not evident in our patient
[11]. The nipple was not retracted and the left axillary
lymphnodes were palpable. The right breast was normal.
On sonography a node measuring 3.4 cm with BI-RADS
score 4 was detected. After core biopsy, the material was
sent for a frozen section (0.6 × 0.5 × 0.6 cm). The diagnosis
was invasive ductal carcinoma (IDC) with histological
grade III and nuclear grade 3 (Figure 2). The patient did
not present himself to the hospital during 1 year. After
1 year, the patient returned to the Medical Service and was
submitted to a left radical mastectomy and axillary dissec-
tion. Histology confirmed an IDC of 2.5 cm, grade 3 and
six out of 23 lymph nodes were positive, staging resulted in
pT4N2Mx (tumor, node and metastatic involvement).
Tumor size and lymph node involvement are two clear
prognostic factors for male patients with breast cancer.
Men with tumors measuring 2–5 cm have a 40% higher
risk of death than men with tumors <2 cm in maximum
diameter. Immunohistochemical analysis showed that the
tumor was positive for the presence of estrogen/proges-
terone receptors and for the human epidermal growth
factor receptor-2 (HER-2). The patient initiated adjuvant
treatment with 4 cycles of TAC (Taxotere, Adriamycin and
Cyclophosphamide). Following adjuvant treatment he was
treated with local radiotherapy, dose 5.000 cGy (25 ×
200 cGy), followed by a treatment with tamoxifen from
2010 until the present (35 months). The bone scintigraphy
showed other pathologic sites at T9, L1, ischium and acet-
abulum (Figure 3), therefore treatment was associated
with pamidronate.
Because the patient was an affected individual with
MBC and familial breast cancer history, he was referred
to a genetic counseling service. Considering his extensivee figure shows a family history of cancer of 2 generations. Father dead
, II.8, II.10, II.11, II.12, respectively) and four brothers dead of unknown
nosed with breast cancer (III.1 and III.2). The age of diagnostic are
Figure 2 Hematoxylin and eosin-stained sections of paraffin-embedded tumour biopsy. The diagnosis was invasive ductal carcinoma (IDC)
with histological grade III and nuclear grade 3. Magnifications A) 100X B) 200x and C) 400X.
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was extracted from peripheral blood [12] and exome ana-
lysis was performed, applying the BROCA test, which is a
targeted capture sequencing approach, to identify all single
base pair substitutions, insertion-deletions, and copy num-
ber variants in all known breast cancer genes (33 genes)
[13,14]. The criteria for genetic screening for breast cancer
genetic assessment was conducted based on NCCN
guidelines v1.2013 (NCCN Clinical Practice Guideline in
Oncology- Genetic/Familial High Risk Familial Assessment:
Breast and Ovarian. Version 1.12).
A large heterozygous genomic deletion was identified,
predicted by read-depth analysis of BROCA sequence to
be chr13: 32,926,826 to 32,930,318 (hg19). A 3,492 nu-
cleotide deletion was detected at BRCA2 sequence,
BRCA2_g.26826_30318del, including exon 14, which isFigure 3 Proband’s bone scintigraphy realized on December, 2nd 200out of frame and is predicted to lead to a stop in exon 15
at codon 2,496. To analyze the mutation effect at tran-
script level, RNA was extracted from FFPE (formalin fixed
paraffin embedded) samples of normal and tumour tissue
followed by RT-PCR reaction. The PCR was performed
utilizing primers against 13 and 15 BRCA2 exons forward
and reverse, respectively (13 F-GCCGATTACCTGTGTA
CCCT; 15 F-GAAAGACGCGTTGCCTTTGT). No amp-
lification was observed in the proband’s samples while for
the controls (70 ng from cDNA from MRC5-V1 cells) a
530 bp product was amplified, as expected (Figure 4),
showing that the deletion is present in both tissues.
BRCA2 gene has 27 exons and there are 14,823 mutations
related in the BIC database. In BRCA2 exon 14, there
are a total of 624 entries for mutations, of which 76 are
distinct mutations, polymorphisms and variants and 409 showing focus of metastasis at T9, L1, ischium and acetabulum.
Figure 4 Mutation effect at transcript level. Agarose gel (1,5%) showing no amplification of proband’s samples using a forward primer in exon
13 and a reverse primer in exon 15 of BRCA2. Total cDNA from two independent RNA extractions from MRC5-V1 cells was used as a positive
control for fragment amplification. A total of 70 ng from cDNA was used in each reaction. The length of the fragment expected is 530 bp.
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found to date in the BRCA1/BRCA2 genes in breast and/
or ovarian cancer families are point mutations or small in-
sertions and deletions scattered over the coding sequence
and splice junctions. Large rearrangements in BRCA1 and
BRCA2 occur in a small percentage (<1%) of patients
tested for hereditary breast and ovarian cancer [15]. More-
over, the mutation was detected in a male patient.
Unfortunately, the patient developed bone metastasis
and died of multiple organ failure in July 2013. He was
still under treatment with TAC and pamidronate.
The proband had two daughters from a first marriage,
whose both had breast cancer, suggesting that this could
be a high penetrance mutation, but it was not possible to
analyze their DNA. The patient had two sons (Figure 1;
III.3 and III.4), both unaffected, the youngest was tested
and he does not carry this mutation.
Some authors suggest [16] that testing might be con-
sidered in men without cancer, or with the diagnosis of
prostate cancer, and a first or second-degree relative di-
agnosed with breast or ovarian cancer before the age of
50 years. They are taught and encouraged for breast self-
examination and to perform twice-yearly clinical breast
examinations.
Male breast tumors are usually found by palpation.
The most common presentation is a painless subareolar
mass (50 – 97%) [17]. About 42% of breast cancer cases in
men are diagnosed in advanced stage (III or IV) because
men do not seek medical attention for breast masses as
quickly as women.
It is estimated that approximately 10% of men with
breast cancer have a genetic predisposition, with BRCA2
being the most prevalent gene mutation and BRCA1 being
less [13,16,18-20]. It is estimated that these mutations
contribute to 4 – 40% of hereditary breast cancer in men
[21], compared to 5 – 10% of female breast cancer [22].Furthermore, the life-time risk of breast cancer in male
BRCA2 mutation carriers is approximately 8 – 10 times
higher than the general population [23]. BRCA2mutations
are also associated with increased risks in men for prostate
cancer and pancreatic cancer, and possibly increased risks
for gallbladder, stomach cancer and melanoma. The oc-
currence frequency of prostate cancer in males with
BRCA2 mutations is approximately 5 times higher than
expected in the general population and the risk to develop
pancreatic cancer in males and females with a BRCA2
mutation is 82.5 times higher and approximately 14 times
higher, respectively [24].
Methods to detect germline mutations in high risk
families are still too expensive, and in Brazil, the socio-
economic reality is far from this technology. However,
next-generation sequencing it is a much more rapid,
simple and cost-effective methodology to detect large
genomic deletion, instead performing Sanger sequencing
and multiplex ligation-dependent probe amplification
analysis (MLPA).
The BRCA2 large heterozygous genomic deletion pre-
sented herein is reported for the first time and this can
help others to understand the phenotype of individuals
carrying this mutation, which is clinically relevant since
it leads to a truncated protein. Finally, this result will
contribute to create awareness for physicians to investi-
gate for germline mutation in men with a family history
of cancer and increase the information of the type of
mutation that can be related to breast cancer develop-
ment in men.
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